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Abstract
Mesenchymal stem cells (MSCs) represent a valuable resource for regenerative medicine treatments for
orthopaedic repair and beyond. Following developments in isolation, expansion and differentiation
protocols, efforts to promote clinical translation of emerging cellular strategies now seek to improve cell
delivery and targeting. This study shows efﬁcient live MSC labelling using silica-coated magnetic
particles (MPs), which enables 3D tracking and guidance of stem cells. A procedure developed for the
efﬁcient and unassisted particle uptake was shown to support MSC viability and integrity, while surface
marker expression and MSC differentiation capability were also maintained. In vitro, MSCs showed a
progressive decrease in labelling over increasing culture time, which appeared to be linked to the
dilution effect of cell division, rather than to particle release, and did not lead to detectable secondary
particle uptake. Labelled MSC populations demonstrated magnetic responsiveness in vitro through
directedmigration in culture and, when seeded onto a scaffold, supportingMP-based approaches to cell
targeting. The potential of these silica-coated MPs for MRI cell tracking of MSC populations was
validated in 2D and in a cartilage repair model following cell delivery. These results highlight silica-
coated magnetic particles as a simple, safe and effective resource to enhance MSC targeting for
therapeutic applications and improve patient outcomes.©2016 The Authors Journal of Tissue Engineer-
ing and Regenerative Medicine Published by John Wiley & Sons Ltd.
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1. Introduction
Over the past decades, a range of iron oxide-basedmagnetic
particles (MPs) have been developed for clinical applica-
tions in the ﬁeld of magnetic resonance imaging (MRI)
(Gilchrist et al., 1957). Superparamagnetic iron oxide nano-
particles (SPIOs) are a speciﬁc class of magnetic particles
known for their application as T2-weighted negative MRI
contrast agents, designed to overcome the inherent low
sensitivity associated with MRI (Bulte and Kraitchman,
2004; Pooley, 2005). Magnetic particles composed of either
a magnetite (Fe3O4) or maghemite (γ-Fe2O3) core (Berman
et al., 2011; Gupta and Gupta, 2005) surrounded by a
biocompatible polymer, such as silica and dextran, have
been used for the labelling and identiﬁcation of cell popula-
tions (Kunzmann et al., 2011). FDA-approved iron-based
particles, such as Endorem (also referred to as Feridex)
and Resovist, have been used as MRI contrast agents in
recent years (Berman et al., 2011; Jasmin Torres et al.,
2011); however, since these products are no longer clini-
cally used, there is a need for validated products offering
low toxicity, biocompatibility and chemical stability under
physiological conditions (Hofmann-Amtenbrink et al.,
2010; Mahmoudi et al., 2011).
While the literature onMPs has largely focused on develop-
ing particle design, synthesis and characterization (McBride
et al., 2013), recent studies have also investigated MPs for
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cell-based applications beyond MRI imaging, as their applied
magnetic ﬁelds have been used to develop new approaches
to enhance transfection (Pickard et al., 2011), induce hyper-
thermia (Kobayashi, 2011), force in vitro aggregation (Fayol
et al., 2013), enable regenerative therapies (El Haj et al.,
2012) and activate cell receptor signalling on the cell mem-
brane (Henstock et al., 2014). Their small size and magnetic
properties, coupled with versatile surface coatings (Gupta
and Gupta, 2005), open a range of new approaches which
could see MPs enhance existing and future regenerative cell
therapies. Such cell-based approaches require the targeted
delivery of functional populations, such asmesenchymal stem
cells (MSCs), which have become a resource of prime
importance for their skeletal regeneration ability (Caplan,
2007; Quarto et al., 2001) but also for their properties of im-
mune modulation (Le Blanc et al., 2003), anti-inﬂammation
(Uccelli, 2008) or trophic secretion (Caplan and Dennis,
2006).MSC-based therapies for tissue repair require auxiliary
approaches which enable in vivo tracking, delivery and
targeting, in order to monitor and improve the retention of
functional cells at the intervention site (Wimpenny et al.,
2012).
In this study, the suitability of MPs presenting a silica
surface with negatively charged silanol groups was investi-
gated for use in human mesenchymal stem cells (MSCs) as
a labelling, imaging and manipulation agent. The labelling
dynamics and cellular response were analysed with a par-
ticular emphasis on markers of cell health, identity and
functional potential of the target population, as well as their
suitability for cell-tracking purposes in an articular model.
Observations presented here can help reﬁne novel applica-
tions of MP labelling and evaluate the resulting health
considerations of future MP-assisted stem cell therapies.
2. Materials and methods
All reagents were purchased from Life Technologies, un-
less otherwise stated.
2.1. Human mesenchymal stem cell cultures
A human bone marrow-derived mesenchymal stem cell
line (hMSCs) (France et al., 2014; Okamoto et al., 2002)
was cultured and expanded under standard cell culture
conditions (37.5°C, 5% CO2) in standard culture medium
consisting of Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% v/v fetal bovine serum
(FBS), 1% v/v non-essential amino acids, 1 mM L-gluta-
mine, 1 mM pyruvate and 1% penicillin–streptomycin.
The cells were passaged using trypsin–EDTA. For some
experiments, hMSCs stably transfected to constitutively
express green ﬂuorescent protein (GFP; gMSCs) following
an established protocol (Peister et al., 2004) were used
under standard cell culture conditions in standard culture
medium to enable ﬂuorescence microscopy.
Primary human mesenchymal stem cells (pMSCs) were
isolated from human bone marrow aspirate (Lonza, UK).
In brief, the bone marrow aspirate was seeded in
ﬁbronectin-coated ﬂasks at a mononuclear cell density of
1.5 × 103 cell/cm2 and cultured for 1 week (37°C, 5%
CO2) in pMSC isolation medium containing low-glucose
DMEM (Lonza Biowhittaker, UK) supplemented with 10%
FBS (Lonza Biowhittaker), 1% L-glutamine (Sigma-Aldrich,
UK) and 1% penicillin–streptomycin (Sigma-Aldrich). A
50% medium change with fresh pMSC isolation medium
was performed after 1 week, followed by a switch 1 week
later to hMSC proliferation medium (high-glucose DMEM
supplemented with 10% FBS, 1% L-glutamine and 1%
penicillin–streptomycin). pMSCs were identiﬁed as those
which had adhered to the tissue-culture vessel after 14 days
in culture.
2.2. Cell labelling with magnetic particles (MPs)
hMSCs and pMSCs were labelled with 1000 nm particles
composed of a maghemite core with a solid unmodiﬁed
silica surface, as previously described (Markides et al.,
2013), using standard (SiMAG) or ﬂuorescently tagged
(ScreenMAG-Silanol) particles, as speciﬁed (Chemicell,
Germany). In brief, adherent cell populations were incu-
bated with MPs (1–10 μg/ml) in medium for 24 h, using
serum-containing or serum-free medium (MRI experi-
ments) as speciﬁed (for cell-labelling experiments, stan-
dard medium containing 10% FBS was used, unless
otherwise stated). The next day, the cells were thoroughly
washed with phosphate-buffered saline (PBS) in order to
remove excess particles that may have settled on the sur-
face of the cell layer or ﬂask.
To measure particle uptake by ﬂow cytometry, cells were
seeded at 7.5 × 103 cell/ml and ScreenMAG-labelled for
24 h. The cells were then harvested, centrifuged at
200 × g for 5 min and resuspended in 200 μl PBS prior to
analysis on a Guava EasyCyte 8HT Flow Cytometer Channel
FL2 with InCyte 2.5 Software (Millipore, USA), comparing
labelled and unlabelled populations to evaluate percentage
uptake based on ﬂuorescent intensity. Analysis was per-
formed using WEASEL (WEHI, Australia), using unlabelled
cells as controls to evaluate increased ﬂuorescence. The
standard particle concentration used in the study was
10 μg/ml, unless otherwise stated, which was shown to
correspond to an intracellular iron load of 20 pg/cell
(Markides et al., 2013).
2.3. Fluorescence imaging of particle uptake
Particle uptake was further evaluated visually using an
array of ﬂuorescent cell dyes and ﬂuorescent microscopy
to evaluate internalization in relation to cell structure.
hMSCs cultured on glass coverslips were labelled with
particles and ﬁxed at room temperature for 15 min in
4% v/v paraformaldehyde (PFA; VWR, UK). After perme-
abilization with 0.1% Triton X-100 for 5 min following two
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tPBS washes, cells were stained for actin ﬁlaments using a
1:41 working solution of 6.6 μM AlexaFluor® 488
phalloidin in methanol. The slides were incubated in a dark
covered container at room temperature for 20 min and then
washed twice with PBS, prior tomounting using Vectashield
mountingmedium (Vector Laboratories, USA). Imagingwas
performed using a Leica TCS SP2 confocal laser-scanning
microscope (CLSM; Leica Microsystems, Germany).
2.4. Prussian blue staining
hMSC cells were grown in monolayer and labelled with
10 μg/ml MPs for 24 h prior to ﬁxing with 4% PFA for
15 min. Immediately prior to addition to the cells, 20%
aqueous solution of hydrochloric acid and 10% aqueous
solution of potassium ferrocyanide were mixed in equal
parts. This staining solution was applied to the ﬁxed
monolayer for 5 min and washed three times with PBS.
Images were acquired using an Eclipse TS100 inverted
microscope (Nikon, Japan).
2.5. Transmission electron microscopy (TEM)
To conﬁrm the cellular location of the particles, samples
were ﬁxed in 3% glutaraldehyde in 0.1 M cacodylate buffer
overnight and post-ﬁxed in 1% aqueous osmium tetroxide
for 30 min. The samples were then dehydrated in a graded
ethanol series and inﬁltrated with Transmit resin (TAAB,
UK), then allowed to polymerize overnight at 70°C. Semi-
thin sections were cut (0.5 μm), using a Reichert–Jung
ultramicrotome, and stained with 2% toluidine blue.
Ultra-thin sections were cut (70–90 nm) using the same
equipment and collected on copper grids, which were then
contrasted using 50% methanolic uranyl acetate and
Reynolds lead citrate (Robards andWilson, 1993). Imaging
was performed on a FEI Tecnai 12 Biotwin TEM (FEI, USA)
with up to 120 kV and ×300 k magniﬁcation.
2.6. Particle labelling measurement
Flow cytometry was used to measure the level of particle
labelling over time. For mitotic arrest, mitomycin C
(Sigma Aldrich, UK) treatment was used to halt cell
division, using a ﬁnal concentration of 10 μg/ml for a
2.5 h incubation at 37°C (Nieto et al., 2007). The cells
were then washed twice with PBS and harvested for use.
Mitotically arrested and control cells were cultured over
a 7 day period, with cells ﬁxed in 4% PFA for analysis on
days 1, 5 and 7. To investigate particle transfer between
co-cultured populations, GFP-expressing MSCs (gMSCs)
labelled with MPs were cultured with unlabelled hMSCs.
Both populations were mitotically arrested prior to co-
culture with samples ﬁxed in 4% PFA each day over 7 days,
before ﬂow-cytometry quantiﬁcation of particle presence
and GFP status.
2.7. Cell surface marker analysis
hMSCs and pMSCs were assessed for expression of
multipotent markers (Dominici et al., 2006), performed
24 h after MP labelling (with SiMAG and ScreenMAG,
respectively) and 14 days after initial labelling, with re-
peated passaging and relabelling every 3 days to maintain
a high MP level throughout. Cells were harvested with
trypsin–EDTA and pelleted by centrifugation for 5 min at
200 × g before washing in PBS. The cell pellets were then
resuspended in 100 μl PBS supplemented with 5 μl anti-
bodies against CD29 (Abcam, UK), CD105, CD34 and
CD73 (AbdSerotec, UK), CD90 and SSEA4 (eBiosciences,
USA) for 30 min at room temperature, before two PBS
washes and ﬂow-cytometry analysis.
2.8. Cell viability assays
The resazurin metabolic assay was performed to determine
metabolic changes, using a working solution consisting of
10% v/v Presto Blue stock solution, prepared according to
themanufacturer’s instructions. After 45min of incubation,
the ﬂuorescent signals of 100 μl samples were measured at
535 nm excitation and 615 nm emission in triplicate, using
an Inﬁnite 200 PRO plate reader and i-control software
(Tecan, Switzerland).
Impact on membrane integrity was assessed using a
Live/Dead® AlexaFluor® 488 ﬁxable viability dye. Cells
were harvested with trypsin–EDTA and pelleted by
centrifugation for 5 min at 200 × g, washed twice with
PBS and resuspended in 100 μl amine-reactive dye work-
ing solution, consisting of 1% v/v amine-reactive DMSO
stock in PBS. Following 15 min incubation at room
temperature, the cells were rinsed twice with PBS and
resuspended in 200 μl PBS prior to measurement on a
Guava EasyCyte 8HT ﬂow cytometer. Unlabelled cells
were used as viable controls and DMSO or PFA ﬁxative
treatments provided toxicity controls.
2.9. Single-cell gel electrophoresis (comet) assay
Potential damage to the DNA was assessed with the alka-
line comet assay (Seedhouse et al., 2006). hMSCs were
grown in monolayer and either left unlabelled or labelled
with 10 μg/ml or 100 μg/ml SiMAG for 24 h. Following
trypsinization, cells were washed once with PBS and re-
suspended in low melting point agarose (Trevigen, UK)
at 105 cells/ml. Comet assay alkaline control cells were
used as a positive control for DNA damage (Trevigen).
Cell-containing agarose was immediately spread on comet
slides (Trevigen) and left to harden before complete
immersion in cell lysis buffer (Trevigen). Lysis was per-
formed overnight at 4°C in the dark. Following this, the
lysis buffer was removed and the slides immersed in a
UV-protected electrophoresis tank containing TBE run-
ning buffer and allowed to stand for 60 min. Voltage
was set at 25 V/CM distance between electrodes and
Magnetic MSC labelling for imaging and improved cell control 2335
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running time at 40 min. Following running, the slides were
removed from the buffer andwashed three times in distilled
water before dipping in ethanol for 1 min and drying over-
night. The dry comet slides were stained with 75 μl 0.2%
SYBR Green in TBE buffer/agarose droplets. The samples
were immediately imaged under a rhodamine ﬁlter, using
an Olympus BX40 microscope. Comet tails were analysed
using Comet Assay III image analysis software (Perceptive
Instruments, UK); 50 comet images were obtained from
each of the duplicate gel spots and each experimental con-
dition was repeated three times; therefore, 600 images
were scored in total for each treatment. The tail moment
was used in all analysis.
2.10. Mesenchymal differentiation
For differentiation assays, hMSCs were incubated for
21 days in the relevant differentiation media. For osteo-
genic assays, cells were seeded at 5 × 103 cells/cm2 in well
plates (Sigma-Aldrich, UK); the medium was then changed
(considered as day 0) every 3 days for 21 days. With either
control medium or osteogenic induction DMEM supple-
mented with 100 nM dexamethasone, 0.05 mM L-ascorbic
acid 2-phosphate and 10 mM β-glycerophosphate. For
adipogenic assays, cells were seeded at 1 × 104 cells/cm2
in well plates (Sigma-Aldrich, UK); the medium was then
changed (considered as day 0) every 3 days for 21 days,
with either control medium or adipogenic induction high-
glucose (4500mg/l) DMEM supplemented with 1 μM dexa-
methasone, 500 μM isobutylmethylxanthine, 10 μg/ml
insulin and 1 μM rosiglitazone. For chondrogenic assays,
cells were seeded at 37.5 × 104 cells/cm2 in ﬂasks for the
labelling duration; cells were then detached and 200 μl
1.25 × 106 cells/ml cell suspensions added to 96-well V-
bottom plates (Nalge Nunc International, USA) and spun
at 450 × g for 10 min. Following 24 h attachment duration,
the medium was then changed every day for 21 days
with either control medium or chondrogenic induction
high-glucose (4500 mg/l) DMEM supplemented with
2 mM L-glutamine, 0.1 μM dexamethasone, 50 μg/ml
ascorbic acid phosphate, 1 mM sodium pyruvate, 40 μg/ml
Proline, 10 ng/ml TGFβ and 1× ITS Liquid Media Supple-
ment (Sigma-Aldrich, UK).
2.11. Differentiation assays
Lipid-containing cells were identiﬁed using oil red O
(Sheng et al., 2007). The cells were washed with PBS
and ﬁxed at room temperature for 15 min in 4% v/v
PFA. The cells were then washed twice with distilled
water and incubated with oil red O working solution
added (180 mg/l oil red O in 60% isopropanol/40%
distilled water) for 30 min at ambient temperature. The
samples were then washed and imaged before extraction
of the incorporated stain with isopropanol to measure
absorption at 510 nm on an Inﬁnite 200 PRO plate reader
and i-control software (Tecan, Switzerland).
Mineralized nodules were identiﬁed using von Kossa
staining (Wang et al., 2006). Cells were washed with
PBS and ﬁxed at room temperature for 15 min in 4%
PFA. The cells were then washed three times with distilled
water and incubated with 1% silver nitrate in distilled
water (Sigma-Aldrich, UK) under a UV lamp for 15 min.
The samples were washed three times with distilled wa-
ter, incubated for 5 min with 2.5% sodium thiosulphate
solution (Sigma-Aldrich, UK), washed again with distilled
water and imaged using an Eclipse TS100 inverted micro-
scope (Nikon, Japan).
Sulphated glycosaminoglycans detected with the dye
1,9-dimethylmethylene blue (DMMB) were used as an
indicator of chondrogenesis. Chondrogenic micromasses
were freeze–thawed three times to partially disaggregate
them, followed by papain digestion (sodium phosphate
0.1 M, cysteine hydrochloride 5 mM, EDTA 5 mM and
papain 45.12 μM in distilled water, pH adjusted to 6.5)
overnight at 60°C. Aliquots of digested sample were
stained with DMMB dye solution (0.03 M sodium formate,
0.046 mM DMMB, 85.5 mM ethanol and 53 mM formic
acid in distilled water), left for 10 min at room tempera-
ture and read for absorbance at 540 nm on an Inﬁnite
200 PRO plate reader and i-control software (Tecan,
Switzerland). Aliquots of digested sample were also taken
for DNA content analysis with CyQUANT® to allow for
normalization. CyQUANT® GR dye/cell-lysis buffer was
added to the samples and incubated for 5 min at room
temperature. The samples were analysed on an Inﬁnite
200 PRO plate reader and i-control software (Tecan,
Switzerland).
2.12. Directed migration assays
For the vertical migration model, hMSCs were labelled
with concentrations in the range 2.5–100 μg/ml alongside
unlabelled control cells for 24 h. The cells were then
harvested and resuspended to a concentration of
1 × 105 cells/ml. 20 μl drops were deposited, in quadru-
plicate, on the inside of a multiwell plate lid, which was
carefully placed to form hanging drops suspended above
humidiﬁed wells. A magnetic array constructed from
10 × 3 mm neodymium magnets (2800 gauss; Magnet
Expert, UK) was placed above each well, and after 24 h
the proportion of cells attached to the undersurface of
the lid was evaluated after toluidine blue staining (0.1%
for 10 min) and imaging using a 41 Megapixel PureView
Zeiss Camera (Nokia, Finland). Quantitative 2D image
density analysis was performed using ImageJ (NIH, USA).
For the transmigration assay, SiMAG-labelled pMSCs
(0, 1 and 10 10 μg/ml) were seeded at a concentration
of 104 cells/collagen transwell insert (Corning, UK) and
allowed to attach for 24 h. The plates were either placed
on a magnetic array mimicking a standard 24-well plate
layout or cultured without a magnetic ﬁeld for 24 h. The
collagen layer was then gently removed and the transwell
completely washed three times with PBS. Migrated cells
located on the underside of the transwell were ﬁxed using
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4% formalin for 1 h, stained with DAPI and imaged using
a ﬂuorescent microscope. Five independent areas of the
well were imaged (top, bottom, left, right and centre)
and averaged for each sample.
2.13. MRI imaging
To establish the ex vivo knee model, chondrocytes were iso-
lated from porcine articular knee cartilage (Staffordshire
Meat Packers, Stoke-on-Trent, UK) 2 h post-slaughter, based
on a technique adapted fromHayman et al. (2006). Cartilage
was carefully removed from the upper condyles of the knee,
ﬁnely diced, weighed and rinsed in PBS and 2% penicillin–
streptomycin. After overnight incubation in chondrocyte
isolation medium consisting of DMEM/HAM’S F12 (Lonza
Biowhittaker, UK), 2% penicillin–streptomycin, 50 μg/ml
sterilized ascorbate (Sigma-Aldrich, UK),1mg/ml clostridial
collagenase (Sigma-Aldrich) and 0.1 mg/ml DNAse (Sigma-
Aldrich), the digested cartilage suspension was ﬁltered
through 100 μm cell strainer and centrifuged at 600 × g
for 10 min. Chondrocytes were seeded at 2 × 104 cells/cm2
and cultured in chondrocyte proliferation medium
(DMEM/HAM’S F12 supplementedwith 10% FBS,1% L-glu-
tamine and 1% penicillin–streptomycin).
The in vitro MRI visibility threshold of SiMAG-labelled
cells populations (0, 1, 5, 10 and 100 μg/ml) was investi-
gated at varying cell densities (5 × 105, 105 and 104) in
2 mg/ml rat tail type I collagen gel (BD Biosciences,
UK). The samples were then imaged using a 2.3 T Brucker
animal scanner (NTU, Nottingham, UK), with MSME
sequences using 1000 ms repetition time, 10.25 ms echo
time with eight echoes, and a matrix size of 256 × 192
with a spatial resolution of 0.469 × 0.625 mm.
Ex vivo imaging was carried out using a cadaveric por-
cine knee model of articular cartilage damage to assess
the visibility threshold of MP-labelled cells in a clinically
relevant model of autologous chondrocyte implantation
(ACI) to treat cartilage damage (Chiang et al., 2005).
Pig legs were processed to remove all surrounding tissue,
using a surgical scalpel. Once the knee had been isolated,
the patellar tendon was sliced and the patella pulled back
to reveal the articulating ends of the femur and tibia. The
knee was then bent to fully expose the upper condyles,
and cartilage ﬂaps were created (1.5 × 0.5 × 1.5 cm)
across the upper condyles of the knee. Two defects were
created on each condyle (left and right), at least 0.5 cm
apart. MP-labelled cells were suspended in a collagen type
1 gel solution (4.5 mg/ml) and injected within the defect
while the knee was in the bent upright position, taking
care to ensure no bubbles or leakage occurred. After the
gels had set (1 h, 37°C) the leg was straightened and
the patella replaced and securely bandaged to prevent
excess movement, before storage at –20°C until imaging
at the MARIARC centre (Liverpool University), using a
Siemens Symphony 1.5 T scanner. One day prior to MR
imaging, the samples were defrosted, placed within a cir-
cularly polarized extremity coil, and double-echo steady-
state (DESS) sequences were applied, in agreement with
MRI scanning conditions implemented in the imaging
and diagnosis of human knee pathologies.
2.14. Statistical analysis
Statistical analysis was in the form of ANOVAs performed
using GraphPad PRISM (GraphPad Software, USA).
Tukey’s post hoc analysis was performed to determine the
signiﬁcance between subgroups of the analysed popula-
tion. Signiﬁcance was shown as *p < 0.05, **p < 0.01,
***p < 0.001 and ****p < 0.0001.
3. Results
3.1. Cytocompatibility study
To evaluate the capacity ofMSCs to take upMPs,monolayer
cultures were incubated overnight with various concentra-
tions of particles. Particle uptake in hMSCs following a
24 h incubation period with MPs was analysed by ﬂuores-
cence microscopy and ﬂow cytometry (Figure 1).
Incubation with increasing doses of MPs led to a
proportional increase in the ﬂuorescence signal measured
for hMSCs (Figure 1A). Time-lapse microscopy (see
supporting information, Video S1) and ﬂuorescence mi-
croscopy (Figure 1B) conﬁrmed particle uptake while
the cells retained morphology after labelling. Prussian
blue staining allowed visualization of the iron-containing
particles present within the cells (Figure 1C). TEM
imaging conﬁrmed the presence of MPs within the cyto-
plasm and highlighted their localization to vesicles found
to congregate around the nucleus (Figure 1D). The
efﬁciency of MP uptake was compared under different
serum concentrations using ﬂow cytometry, which dem-
onstrated a dose-dependent negative effect of serum on
cell labelling (Figure 1E).
Following uptake, particle retention was analysed over
time in culture (Figure 2). In dividing hMSCs, MPs were
found to be progressively diluted until day 7, when they
were not detected (Figure 2A). In mitotically arrested
cells, however, the particles were retained more efﬁciently
and showed a signiﬁcant retention compared to untreated
cells at day 7, suggesting that the MP load might be
divided between daughter cells. Observation of labelled
cells showed the occasional presence of some isolated
particles within cell projections (Figure 2B).
To investigate the fate of the particles over time, a co-
culture experiment was set up to examine whether MPs
may be transferred between labelled and unlabelled hMSC
populations (Figure 2C). GFP-expressing MSCs (gMSCs)
labelled with MPs were mixed with control unlabelled
hMSCs, and over 7 days in co-culture cells were analysed
by ﬂow cytometry to evaluate the proportion of MP-
containing cells within each MSC population. While a
decrease in the percentage of MP-containing gMSCs was
seen over time, there was no detectable appearance of
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MP-containing cells in the unlabelled hMSC population
over 7 days.
The effect of MP exposure on cell identity was analysed
through surface marker analysis and cell integrity assays
(Figure 3). Using markers associated with MSCs, compara-
ble positive expression of CD90, CD105, CD73, SSEA4 and
CD29, with negative expression of CD34, was conﬁrmed be-
tween labelled and unlabelled control populations 24 h after
Figure 1. MSCs labelled with ﬂuorescently labelled MPs, analysed using both ﬂow cytometry and microscopy. (A) Flow cytometry anal-
ysis (left) and corresponding quantiﬁcation (right), showing increased labelling with increasing MP concentrations (***p < 0.001,
****p < 0.0001; n = 3). (B) Fluorescence imaging of hMSCs labelled with 10 μg/ml particles, showing MPs (yellow), cell outline
(phalloidin; green) and nuclear counterstain (Hoechst 33342; blue); bar = 25 μm. (C) Prussian blue staining, highlighting internalized
iron-rich MPs within the cell; bar = 100 μm. (D) TEM imaging of MPs, showing that internalized particles are contained within vesicles
(arrowhead), which merge into larger vacuoles (arrow) near the nucleus (*); bar = 5 μm (top) and 10 μm (bottom). (E) Negative effect
of serum concentration on the efﬁciency of MP uptake, measured at 24 h after labelling (*p < 0.05, **p < 0.01, ****p < 0.0001; n = 3).
[Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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labelling (Figure 3A). Cultures exposed to serial MP label-
ling every 3 days for 14 days tomaintainmaximumdose sim-
ilarly demonstrated retained marker expression, conﬁrming
that exposure to MPs did not elicit a signiﬁcant change in
marker identity (see supporting information, Figure S1).
The effect of MP exposure was further investigated
through metabolic assays of MSCs labelled with increas-
ing doses of SiMAG MPs, using a resazurin-based dye,
Presto Blue. The data gathered demonstrated a slight
increase in metabolic activity at low particle doses and a
decreased metabolic activity associated with very high
doses 24 h after labelling (Figure 3B). This increased met-
abolic activity at low MP doses appeared to be lost 48 h af-
ter labelling (data not shown). Cell membrane integrity,
assessed using ﬂow cytometry, indicated that no effect of
MP labelling could be detected 24 h (Figure 3C) after
labelling, for either pMSCs cells or hMSCs.
Since MPs were found to accumulate close to the nu-
cleus, their possible effect on cellular DNA was examined
using the comet assay, which provides a sensitive measure
of DNA damage throughout the population (Figure 3D).
No statistically signiﬁcant increase in DNA damage was
observed at 10–100 μg/ml when compared to unlabelled
MSC controls (p > 0.05).
3.2. Application of MSC labelling for regenerative
medicine
After establishing the cytocompatibility of particle label-
ling, the efﬁciency of the differentiation response obtained
under various culture conditions was evaluated in MSCs.
hMSCs, either unlabelled or labelled with SiMAG, were
treated with osteogenic, adipogenic and chondrogenic
media for 7 and 14 days to measure their response with
and without MP exposure (Figure 4). After 21 days in
culture with relevant differentiation media, histological
staining (Figure 4A–C) showed successful responses, as
detected through mineral deposition (von Kossa staining
for the osteogenic condition), lipid accumulation (oil red
O staining for the adipogenic condition) and glycosamino-
glycan (GAG) production (Alcian blue staining for the
chondrogenic condition). Subsequent quantitative assays
revealed no signiﬁcant difference between unlabelled and
MP-labelled cell populations for the osteogenic alkaline
phosphatase activity and alizarin red O assays (Figure 4D,
E) or for adipogenic oil red O staining (Figure 4F). Quanti-
tation of GAG formation in response to chondrogenic
treatment (Figure 4G) showed no detrimental effect of
MP labelling, which produced a slight detectable increase
Figure 2. Kinetics of MSC particle retention after labelling with 10 μg/ml particles. (A) Flow-cytometry analysis of MPs in labelled
cells up to 7 days after labelling, showing gradual decrease in dividing cell populations (light grey), while particle dilution is reduced
by mitomycin C-mediated inhibition of cell division (dark grey) (*p < 0.05, ****p < 0.0001; n = 3). (B) Fluorescence microscopy of
phalloidin staining (green) with DAPI counterstain (blue), showing rare particles (red) detected in cell processes. (C) Distribution of
MPs between a labelled (population 1, gMSCs) and unlabelled (population 2, hMSCs) MSC population, analysed by ﬂow cytometry
over 7 days of co-culture, showing no evidence of secondary particle uptake; statistical analysis, showing labelling of population 1
between days 0–4 and 6 compared to day 7 but no statistically signiﬁcant labelling present in population 2 on any day
(***p < 0.001; n = 2). [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
Magnetic MSC labelling for imaging and improved cell control 2339
© 2016 The Authors Journal of Tissue Engineering and Regenerative Medicine Published by John Wiley & Sons Ltd. J Tissue Eng Regen Med 2017; 11: 2333–2348.
DOI: 10.1002/term
in signal compared to unlabelled controls. These data dem-
onstrate no reduction in differentiation capacity following
particle labelling.
The iron core present in SiMAG particles makes them
susceptible to magnetic forces, a feature potentially bene-
ﬁcial for novel tissue-engineering approaches. In order to
test whether MSC labelling with SiMAG could provide
added control over the behaviour of the cells, a migration
assay was run to measure the cellular response in vitro
(Figure 5). When exposed to a permanent magnet located
above the samples for 24 h (Figure 5A), labelled cells
displayed a signiﬁcant higher vertical migration towards
the magnet when compared to unlabelled samples, which
failed to migrate and adhere. When observing cells re-
cruited to the lid in response to magnet exposure, cells
labelled with higher MP concentrations appeared to aggre-
gate over a smaller, more deﬁned area at the centre of the
lid, rather than spread over a larger surface area, as seen at
the lower dose (2.5 μg/ml), possibly due to a stronger cell
response at the point of highest ﬁeld strength, but this 3D
aggregation could not be accurately quantiﬁed using this
2D adherence assay.
Figure 3. Cell integrity assessment after particle uptake. (A) MSC marker identity analysed by ﬂow cytometry, demonstrating no dis-
cernible change in hMSC marker expression following particle labelling (red, 10 μg/ml) compared to unlabelled cells (blue) and the
isotype control (grey). (B) Metabolic activity assessed through a resazurin analogue (Presto Blue®) at 24 h, demonstrating no signif-
icant negative effect of particle uptake at therapeutic doses (up to 50 μg/ml) when compared to unlabelled controls and DMSO-me-
diated toxicity (**p < 0.01, ****p < 0.0001; n = 3). (C) Cell membrane integrity assay, showing stable membrane integrity 24 h after
labelling with MPs (10 μg/ml); statistical signiﬁcance calculated compared to DMSO-treated or ﬁxed cells (****p < 0.0001; n= 3), no
statistically signiﬁcant difference between treatment groups. (D) DNA integrity analysed using the comet assay, showing no statisti-
cally signiﬁcant DNA damage in labelled cells at 10 and 100 μg/ml; statistical signiﬁcance between induced damage (positive control)
and other conditions (****p < 0.0001; n = 680), no signiﬁcant difference between unlabelled and MP-labelled conditions. [Colour
ﬁgure can be viewed at wileyonlinelibrary.com]
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Figure 4. MSC differentiation in the presence or absence of MPs. (A–C) Differentiation potential under (left panel) standard culture
medium or (right panel) differentiation treatment of the hMSC populations towards (A) osteogenic, (B) adipogenic and (C)
chondrogenic lineages, monitored by von Kossa, oil red O and Alcian blue staining, respectively: MP-labelled cell populations
(10 μg/ml) were compared to unlabelled populations, with no detectable decrease in differentiation in vitro. (D, E) Quantitative as-
sessment of osteogenic response performed at 7 (alkaline phosphatase activity) and 14 (alizarin red S extraction) days, showing sta-
tistically signiﬁcant response to induction medium (grey bars) compared to untreated controls (black bars). (F) Adipogenic induction
was measured using oil red O extraction, demonstrating no statistically signiﬁcant change in lipid accumulation at either concentra-
tion. (G) Chondrogenic response, assessed using the DMMB assay normalized to DNA content, showing increased GAGs in both
unlabelled and labelled populations compared to their standard medium-treated equivalents (****p < 0.0001; n = 5). [Colour
ﬁgure can be viewed at wileyonlinelibrary.com]
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To conﬁrm themagnet-assistedmigration response of cells
labelled using particle concentrations previously shown to
maintain cellular integrity, a further experimental model
was used, inwhichMSCswere seeded onto a porous collagen
scaffold and exposed to amagnetic ﬁeld (Figure 5B). Cells la-
belled with 10 μg/ml MPs showed a signiﬁcantly enhanced
migratory capacity compared to unlabelled cells (p< 0.001).
SiMAG particles can also act as potential contrast agents,
which could allow post-delivery of cellular therapies for
applications such as cartilage repair. In such approaches, an
exogenously expanded cell population would be delivered
to a discrete site, where it would need to be retained in order
to promote local tissue repair (El Haj et al., 2014). The ability
to image and monitor the implanted cells would allow mon-
itoring of the therapy over time (Markides et al., 2013). In
order to identify the variables for cell tracking after labelling,
the MRI visibility thresholds required in terms of particle
concentration and cell number were established ﬁrst
in vitro and then in a preclinical large animalmodel of cell in-
jection (Figure 6). When monitored in vitro (Figure 6A),
SiMAG-labelled MSCs and chondrocytes were clearly
detectable by MRI with signiﬁcant dose-dependent contrast
when using doses in the range 104–0.5 × 106 cells. T2
eff
(Figure 6B)was seen to decreasewith increasing cell numbers
and particle concentrations corresponding to an increasing
Fe content. A minimum visibility threshold of 5 μg/ml used
with 5× 105 labelled cells was identiﬁed in vitro. The detect-
ability of MSC and chondrocyte cell populations after SiMAG
labelling was found to be comparable in this model.
To further evaluate imaging capability in vivo, labelled
cell populations were resuspended in a collagen type I
gel, a substrate widely used in cartilage tissue engineering
(Deponti et al., 2013), injected into a porcine knee model
(Chiang et al., 2005) and MR-imaged using speciﬁc T2-
weighted sequences (Figure 6C). In this clinically relevant
model, the effect of particle concentration on MRI detec-
tion was analysed by implanting varying cell doses (104,
105 and 5 × 106) of SiMAG-labelled cells to determine
the visibility threshold, using two particle concentrations
(5 and 10 μg/ml). A combination of 105 cells labelled with
10 μg/ml was found to provide suitable contrast to enable
graft detection by MRI within the host tissue.
Figure 5. Migration of SiMAG-labelled MSCs in vitro. (A) Hanging drops prepared with cells labelled with increasing MP concentra-
tions were incubated in the presence or absence of magnets placed on the upper side of the lid; after 24 h, surface areas covered by
cells recruited to the surface of the lid (inserts) were imaged and measured (****p < 0.0001; n= 4). (B) MSCs labelled with MPs (0, 1
and 10 μg/ml) over a 24 h period within a collagen transwell system and exposed to a magnet for 24 h; migrated cells counted as the
average of ﬁve ﬁelds of view on the underside of each transwell (***p < 0.001; n = 3)
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4. Discussion
4.1. Efﬁcient unassisted labelling of hMSCs
Magnetic particles offer interesting properties for a multitude
of biological and biomedical applications. Superparamagnetic
iron oxide nanoparticles have already demonstrated clinical
efﬁcacy and safety for MRI imaging (Colombo et al.,
2012) and are now being investigated for more advanced
theranostic applications for cell tracking and manipula-
tion (Corot et al., 2006; Hu et al., 2014). MRI agents are
developed to be bio-inert, in order to minimize
interaction with the cells within the body. Conversely,
cell-labelling agents must interact with the cell of interest
to enable labelling without impacting upon its normal
function. Thus, characterization of cell–MP interactions
needs to be thoroughly assessed for advanced applica-
tions in cell-based therapies. In this study, we evaluated
the suitability of commercially available 1 μm silica-
coated particles as a non-toxic labelling agent for cell
tracking and manipulation towards both in vitro and
in vivo applications.
24 h of incubation of MSCs with MPs was found to allow
efﬁcient labelling of the cell population, with > 95% of
cells labelled at 10 μg/ml, as measured by ﬂow cytometry.
This is in line with previous publications describing
Figure 6. MRI tracking of SiMAG-labelled hMSCs and chondrocytes. (A, B) Increasing MP concentrations (1, 5 and 10 μg/ml) and cell
doses (105 cells, 5 × 105 cells), showing the MRI visibility threshold of labelled MSCs presented as (A) a T2
eff map and (B) a corre-
sponding T2
eff plot. (C) Coronal DESS image of labelled chondrocytes implanted in a porcine knee joint (left condyle 105 cells, right
condyle 5 × 105 cells), analysed by MRI using 5 μg/ml (upper panel) and 10 μg/ml (lower panel) MP concentrations, showing
hypo-intense regions of signal voids (yellow arrows); red lines highlight the region of interest (ROI). [Colour ﬁgure can be viewed
at wileyonlinelibrary.com]
Magnetic MSC labelling for imaging and improved cell control 2343
© 2016 The Authors Journal of Tissue Engineering and Regenerative Medicine Published by John Wiley & Sons Ltd. J Tissue Eng Regen Med 2017; 11: 2333–2348.
DOI: 10.1002/term
near-100% cell labelling using visual inspection following
Prussian blue staining or iron measurements
(Balakumaran et al., 2010; Kostura et al., 2004; Liu et al.,
2011; Markides et al., 2013; Pawelczyk et al., 2006). A dose
of 10 μg/ml was selected as the standard labelling concen-
tration for MSCs, which was comparable to other reports
(7 μg/ml, Liu et al., 2011; 25 μg/ml, Kostura et al., 2004).
Cell labelling experiments demonstrated rapid uptake
of MPs into MSCs, resulting in efﬁcient cell labelling with-
out the need for an added chemical carrier. Previous
studies have suggested that stem cell populations may
beneﬁt from assisted MP uptake through cellular
targeting (Lewin et al., 2000) or the use of transfection
agents, including polyethylenimine, protamine sulphate
and polylysine (Arbab et al., 2004; Balakumaran et al.,
2010; England et al., 2013; Jing et al., 2008a; Kostura
et al., 2004; Schafer et al., 2010). Interestingly, past re-
ports have mentioned inefﬁcient uptake by rat MSCs (Jing
et al., 2008b) and undetectable uptake with human MSCs
(Kostura et al., 2004) when different particles were used
alone. In contrast, our results conﬁrm highly efﬁcient up-
take of the SiMAG particles in the absence of any addi-
tional facilitator, in line with observations carried out in
other stem cell populations (Chen et al., 2013). Particle
surface modiﬁcations inﬂuence the characteristics of size,
charge, toxicity and degradability of the particle (Li et al.,
2013) and have previously been reported to inﬂuence
particle–cell interactions (Gupta and Gupta, 2005;
Sakhtianchi et al., 2013; Zhao et al., 2011). The SiMAG
particles used here were silanol-coated, presenting an ac-
tivated Si–OH surface arrangement. One of the main ben-
eﬁts of the silanol surface is a high colloidal suspension
stability, even in high volume fractions, through pH
changes and electrolyte disturbances (Mulvaney et al.,
2000), all of which are likely to occur to some degree dur-
ing application in a physiological environment. When
silanol-coated MPs come into contact with the membrane,
their association with the phosphatidyl choline-rich re-
gions of the membrane (Zhao et al., 2011) is thought to
elicit a membrane-wrapping effect as other regions associ-
ate with the rigid curvature of the silanol surface. The
subsequent entry of the MPs is dependent upon the en-
ergy released through the exothermic membrane-
wrapping effect and the energy required to bend the
membrane around the MP completely. In this situation,
the dense nature of these MPs is considered to decrease
the energy required for deformation of the membrane,
thus facilitating engulfment (Zhao et al., 2011), as sug-
gested by the report that larger MPs are more thermody-
namically favourable for endocytosis (Slowing et al.,
2009). Surface properties of the particles may also inﬂu-
ence their interaction with natural proteins from serum
(Wiogo et al., 2011). The data presented here further
demonstrate that the presence of serum diminishes
SiMAG particle labelling in a dose-dependent manner, po-
tentially due to diminished accessibility of the surface
silanol groups to the membrane, in line with previous re-
ports supporting cell loading in serum-free conditions
(Wilhelm and Gazeau, 2008).
The efﬁcient uptake of the SiMAG particles allowed la-
belled stem cell populations to be monitored through both
their iron content and ﬂuorescent analysis techniques.
Particles appeared to cross the extracellular membrane,
possibly through membrane wrapping and engulfment,
as previously described for silica particles (Zhao et al.,
2011), although the exact nature of this process requires
further examination. Once inside the cell, the particles ac-
cumulated at a central location inside endosome-like
structures proximal to the nucleus, and no particle was
observed inside the nuclear space, likely due to their mi-
cron size and contrary to what has been reported for par-
ticles <70 nm (Chen and von Mikecz, 2005). Such an
intracellular particle distribution has previously been
observed in MSCs (Chang et al., 2012; Neuberger et al.,
2005) and other cell types (Robert et al., 2010b; Sun
et al., 2012; Wilhelm and Gazeau, 2008).
4.2. Cellular compatibility
Whilst previous studies have described the use of different
particle types for cell labelling, few have focused on the
potential implications of MP labelling for MSC health
and function. Among these, most reports have investi-
gated the biocompatibility of smaller MPs used with an
auxiliary labelling reagent (Arbab et al., 2004;
Balakumaran et al., 2010). Here, the suitability of SiMAG
labelling for humanMSCs was carefully examined through
a range of parameters reﬂecting the integrity and cell
health of labelled MSCs. Previously published studies on
MP cytocompatibility have largely relied on the assess-
ment of cell morphology combined to MTT/MTS assays;
however, these have demonstrated questionable reliability
for particle and nanomaterials studies (Laaksonen et al.,
2007). A resazurin-based metabolic measurement was
therefore selected here, and indicated a slight increase in
metabolic activity after particle labelling at low doses of
particle uptake. This mild effect, which has been men-
tioned in different experimental conditions, could be
linked to homeostatic mechanisms increasing lipid mem-
brane synthesis in the cell to compensate for extracellular
membrane disturbance associated with particle internali-
zation (Kowalski et al., 1972; McNeil and Steinhardt,
1997). Similarly, MSC surface marker expression analysed
before and after labelling showed that both primary and
established MSCs retained their cell identity (Dominici
et al., 2006). This matches observations reported for dif-
ferent models and labelling conditions, which reported
no signiﬁcant change in MSCs (Balakumaran et al.,
2010), and similar stable marker expression in
haematopoietic stem cell populations (Arbab et al., 2004).
Although previous studies have suggested good MP
cytocompatibility for cell cultures (Budde and Frank,
2009; Heymer et al., 2008; Li et al., 2013), some observa-
tions using small-sized MPs (60 nm) have described
changes in MSC migration, colony-formation efﬁciency
and even differentiation after particle labelling (Schafer
et al., 2009). Similar MP concentrations have also been
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reported to cause signiﬁcant toxicity in neuronal and glial
cells, while they did not appear to affect other cell types,
such as cardiomyogenic and pancreatic cells (Laurent
et al., 2012; Mahmoudi et al., 2011). It is therefore impor-
tant to evaluate the toxicity of each MP labelling protocol
to be used in the target cell model for the application con-
sidered. MP-related toxicity may arise from the leaching of
ions from the metal core and the biodegradation polymer
coating, which could cause oxidative stress (Kim et al.,
2011) through the leaching of metal ions from the core, or
the release of oxidants by enzymatic degradation of the
MPs (Mahmoudi et al., 2012). Although iron can be metab-
olized in the human body (Berry, 2005; Bulte et al., 2009;
Henning et al., 2009; Ju et al., 2006; Kim et al., 2010a), high
quantities of Fe can impair viability and normal cell func-
tion (He et al., 2007; Li et al., 2013), underlining the need
for a suitable balance between high Fe incorporation and
safe cell function. Particle concentrations in the range 2.8–
400 μg/ml have been reportedly used for in vivo tracking
(Farrell et al., 2009; He et al., 2007; Jing et al., 2008b;
Kim et al., 2010b). The particle concentration chosen for
this study (10 μg/ml), which was selected within the lower
end of this range, showed no signiﬁcant effect on cell viabil-
ity or on the level of DNA damage in theMSC population, as
measured by the comet assay. This was true even for higher
concentrations (100 μg/ml) and is in line with other studies
that have shown low toxicity of both Fe3O4- and Fe2O3-
based particles (Karlsson et al., 2009).
In addition to preserving the health of labelled cell
populations for future cell therapies, maintaining their
functionality is equally critical if they are to deliver a thera-
peutic effect. Reports published to date have provided
mixed results for the impact of MPs onMSC differentiation.
While a majority of studies reported no signiﬁcant change
based on histological or molecular assays, some negative ef-
fects on chondrogenesis have been observed (Bulte et al.,
2004; Kostura et al., 2004). To examine the suitability of
SiMAG-labelled MSCs to fulﬁl a therapeutic role, we exam-
ined their ability to differentiate into the osteogenic,
adipogenic and chondrogenic lineages and found it to be
maintained when examined both qualitatively and quanti-
tatively. Bone nodules and lipid droplets were present in
their respective cultures, with no statistically signiﬁcant dif-
ferences between unlabelled and labelled cell populations.
Chondrogenic differentiation yielded micromass pellets
demonstrating positive staining of glycosaminoglycans
(GAGs) for both control and MP-labelled cultures. Closer
examination revealed an increase in GAGs measured in
MP-labelled pellets compared with the unlabelled samples,
which could be due to more efﬁcient centrifugal aggrega-
tion of the MP-labelled cells, as observed in our culture,
since this is an important experimental parameter for the
establishment of micromass cultures.
4.3. Control of target cell populations
The possible dilution of the particle load by either exocy-
tosis or cell division represents an inherent limitation of
MPs and MRI-based tracking in cell-based therapies,
which could be of concern in long-term animal studies.
MSC labelling was detected here during a 7 day period
in the case of dividing cell populations, beyond which
the intracellular particle concentrations returned to
control levels. However, this was not solely dependent
upon cell division, as previously observed with smaller
particles (Kim et al., 2012; Wilhelm and Gazeau, 2008),
since non-dividing populations also demonstrated particle
loss, albeit at a reduced rate. Arrested cells still demon-
strated around 30% labelling 7 days after labelling,
suggesting the occurrence of particle release or biodegra-
dation in addition to mitotic dilution. Particle loss has
been described as size-dependent, with smaller particles
reportedly exocytosed at a faster rate than larger particles
(Sakhtianchi et al., 2013). Interestingly, this would ﬁt
with the observation of MP-labelled mouse MSCs
implanted subcutaneously, showing halving of the MRI
signal over 3 days and over one-third of the initial signal
detected by day 7 (Liu et al., 2011). Berman et al.
(2011) suggested particle decrease to be an indicator of
viable cells, as non-viable cells may also retain the parti-
cles due to an inability to divide or actively exocytose.
It is unclear whether magnetic labelling of MSCs may
be associated with particle loss in vivo, and whether this
may lead to subsequent unspeciﬁc labelling through
secondary particle uptake by an unintended population.
Results from our co-culture model combining labelled
and unlabelled MSCs showed that the gradual loss of par-
ticles from a labelled cell population did not result in any
signiﬁcant uptake by neighbouring unlabelled popula-
tions. This suggested that transfer of particles either di-
rectly or indirectly through release into the medium is
not occurring at a population level. This absence of appar-
ent secondary particle uptake may be due to the presence
of protein coronas on released particles, obstructing the
surface silanol groups from associating with the mem-
brane (Foldbjerg et al., 2013; Zhao et al., 2011), which
could decrease subsequent binding and cell internaliza-
tion. This may represent a long-term experimental and
safety beneﬁt ensuring limiting possible leakage of the la-
bel from the target cells to unrelated cell populations
in vivo. Particles released in vivo may, furthermore, be
phagocytosed by macrophages, a process typically more
efﬁcient for larger particles, such as the ones used here,
than for smaller ones (Burtea et al., 2008). This would fur-
ther reduce the amount of released particles available for
secondary uptake and limit the putative unspeciﬁc label-
ling of surrounding tissues.
The use of MRI for cell-based therapies has a dual
purpose. Not only can it precisely image the anatomical
damage site and track implanted cells but it can also eval-
uate the extent of the repair process at the damage site
(Beckmann et al., 2003; Henderson et al., 2003). It is
therefore important to analyse the extent to which
implanted cell populations could be detected within ana-
tomical structures in a realistic clinical model, such as
the porcine knee model presented here, which offers di-
mensions in line with that of human tissue. Implantation
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of SiMAG-labelled cells generated signiﬁcant contrast
within this system and was clearly detected against ana-
tomical structures. The visibility threshold of SiMAG-
labelled cells using a 1.5 T scanner was found to be in agree-
mentwith the threshold established ex vivo (105 cells labelled
with 5–10 μg/ml). These values are compatible with pub-
lished studies, varying from single cell detection with 11.7 T
scanning and μm-sized particles (Bulte and Kraitchman,
2004; Li et al., 2009) to the detection of 1× 106 cells labelled
with 12 μg/ml using a 3 T machine (Chen et al., 2012). The
results presented here thus conﬁrm that SiMAG-based MSC
labelling can meet the technical criteria outlined for use in
preclinical studies (Frank et al., 2004).
5. Conclusions
Beyond imaging, magnetic particles are widely exploited in
separation techniques for cell suspensions (Plouffe et al.,
2015). In vitro experiments carried out in this study con-
ﬁrm that their use can be applied to the spatial control of
cell populations. Contactless magnetic control of cell move-
ment can further enhance patterning and seeding proce-
dures for both 2D culture and for 3D tissue-engineered
scaffolds (Robert et al., 2010a; Yanai et al., 2012). Although
ex vivo models have not reported consistent magnetically-
driven migration (Schafer et al., 2010), possibly due to var-
iations in the particles and magnets used, such targeting
approaches may open novel therapeutic applications using
permanent magnet-, electromagnet- or MR-assisted cell de-
livery (El Haj et al., 2012; Riegler et al., 2010; Robert et al.,
2010a; Vaněček et al., 2012).
Emerging MSC therapies, such as Prochymal, currently
involve the use of high cell doses (in excess of 108 cells)
(Hare et al., 2009), which may in the future be reduced
through improved cell delivery strategies, such as
magnetically-assisted cell targeting, to reduce the dose
needed. Careful prior assessments of the particle uptake,
retention proﬁle and biological responses associated with
such strategies will be critical to ensure the safe develop-
ment of enhanced targeting therapies. A recent report
introducing the in vivo labelling of stem cells prior to their
harvest and allogeneic use (Khurana et al., 2013)
underlined the requirement to ascertain the cellular
innocuousness of MPs for the targeted population. The
data presented in our study support the suitability of
1 μm SiMAG superparamagnetic iron oxide particles as a
possible cell tracking and cell manipulation agent for stem
cell-based therapies. Their large size and coating proper-
ties, facilitating uptake, biocompatibility and visibility for
MRI, make them favourable candidates for further
in vivo preclinical research into advanced tissue engineer-
ing approaches.
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Figure S1. Long-term marker expression in MSC cultures analysed after 14 days of particle labelling
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